Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications

Stock Information for Bolt Biotherapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics to Participate in Upcoming March Conferences
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.